Baxter International Inc. (BAX)
NYSE$27.84-0.8 (-2.79%)
Market Cap
$14.69B
Sector
Healthcare
Industry
Medical—Instruments & Supplies
Rank in Sector
452 of 893
Rank in Industry
24 of 46
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $75M | ||
| $60M | ||
| $56M |
BAX Insider Trading Activity
BAX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
About Baxter International Inc.
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical …
Insider Activity of Baxter International Inc.
Over the last 12 months, insiders at Baxter International Inc. have bought $0 and sold $0 worth of Baxter International Inc. stock.
On average, over the past 5 years, insiders at Baxter International Inc. have bought $0 and sold $13.49M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 19,560 shares for transaction amount of $1.61M was made by Martin Sean (SVP and General Counsel) on 2020‑03‑30.
List of Insider Buy and Sell Transactions, Baxter International Inc.
| 2024-03-01 | Sale | Mason Jeanne K | EVP, Chief HR Officer | 64,488 0.0126% | $40.61 | $2.62M | -12.71% | |
| 2023-02-21 | Sale | Kunzler Jacqueline | SVP, Chief Quality Officer | 3,813 0.0008% | $40.50 | $154,427 | -0.36% | |
| 2023-01-17 | Sale | Mason Jeanne K | SVP, Human Resources | 59,477 0.0118% | $44.70 | $2.66M | -8.36% | |
| 2022-04-05 | Sale | STROUCKEN ALBERT P L | 1,215 0.0002% | $76.63 | $93,105 | -26.35% | ||
| 2022-04-05 | Sale | HELLMAN PETER S | 2,827 0.0006% | $75.76 | $214,174 | -26.35% | ||
| 2022-04-01 | Sale | FORSYTH JOHN D | 1,005 0.0002% | $77.68 | $78,068 | -27.91% | ||
| 2022-03-01 | Sale | FORSYTH JOHN D | director | 1,005 0.0002% | $84.82 | $85,244 | -30.02% | |
| 2022-02-28 | Sale | Stevens Brian | SVP, CAO and Controller | 2,500 0.0005% | $85.50 | $213,757 | -30.69% | |
| 2022-02-14 | Sale | Mason Jeanne K | SVP, Human Resources | 54,143 0.0107% | $85.02 | $4.6M | -29.86% | |
| 2022-02-02 | Sale | Chen Thomas F | director | 1,680 0.0003% | $84.53 | $142,010 | -28.83% | |
| 2022-02-01 | Sale | FORSYTH JOHN D | director | 1,005 0.0002% | $85.59 | $86,018 | -27.59% | |
| 2021-11-01 | Sale | Martin Sean | SVP and General Counsel | 21,450 0.0043% | $79.57 | $1.71M | -6.91% | |
| 2021-08-02 | Sale | Martin Sean | SVP and General Counsel | 19,800 0.004% | $77.26 | $1.53M | +2.65% | |
| 2021-04-12 | Sale | Frye Andrew | SVP, President, APAC | 21,998 0.0044% | $84.79 | $1.87M | -3.27% | |
| 2021-04-05 | Sale | STROUCKEN ALBERT P L | director | 9,980 0.0013% | $57.91 | $577,942 | -3.93% | |
| 2021-04-05 | Sale | HELLMAN PETER S | director | 9,980 0.002% | $84.56 | $843,909 | -3.93% | |
| 2020-11-02 | Sale | Martin Sean | SVP and General Counsel | 94,002 0.0184% | $78.67 | $7.4M | +3.33% | |
| 2020-09-14 | Sale | FORSYTH JOHN D | director | 620 <0.0001% | $57.42 | $35,604 | -3.00% | |
| 2020-09-03 | Sale | Kunzler Jacqueline | SVP, Chief Quality Officer | 5,314 0.0011% | $85.87 | $456,313 | -3.32% | |
| 2020-08-03 | Sale | GAVIN JAMES R III | director | 29,798 0.0061% | $86.41 | $2.57M | -1.96% |
Total: 210
Insider Historical Profitability
6.81%
| Baxter Healthcare SA | 10 percent owner | 2603295 0.5075% | $74.56M | 1 | 0 | <0.0001% |
| KRAEMER HARRY M JANSEN JR | Chairman and | 694556 0.1354% | $19.89M | 1 | 0 | +11.71% |
| PARKINSON ROBERT L JR | Chairman of the Board & CEO | 465485 0.0908% | $13.33M | 2 | 6 | +5.41% |
| JEHARAJAH NEVILLE J | Corporate Vice President | 127603 0.0249% | $3.65M | 1 | 0 | +8.04% |
| GREISCH JOHN J | Corporate Vice President | 90419 0.0176% | $2.59M | 2 | 2 | +1.84% |
| Martin Sean | SVP and General Counsel | 42281 0.0082% | $1.21M | 1 | 3 | <0.0001% |
| STROUCKEN ALBERT P L | 34127 0.0067% | $977,397.28 | 6 | 9 | +7.78% | |
| HELLMAN PETER S | 28822 0.0056% | $825,462.08 | 2 | 8 | +15.48% | |
| Devitt Blake E | director | 16541 0.0032% | $473,734.24 | 2 | 3 | +4.94% |
| ALMEIDA JOSE E | Chairman of the Board and CEO | 11691 0.0023% | $334,830.24 | 1 | 0 | +11.45% |
BAX Institutional Investors: Active Positions
| Increased Positions | 359 | +31.41% | 46M | +9.74% |
| Decreased Positions | 508 | -44.44% | 33M | -6.93% |
| New Positions | 109 | New | 12M | New |
| Sold Out Positions | 175 | Sold Out | 7M | Sold Out |
| Total Postitions | 994 | -13.04% | 483M | +2.81% |
BAX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $1.83M | 12.39% | 63.55M | +1M | +1.77% | 2024-12-31 |
| Vanguard Group Inc | $1.75M | 11.84% | 60.76M | +462,928 | +0.77% | 2024-12-31 |
| Dodge & Cox | $1.45M | 9.82% | 50.38M | +6M | +12.96% | 2024-12-31 |
| Pzena Investment Management Llc | $968,447.00 | 6.56% | 33.64M | +1M | +4.39% | 2024-12-31 |
| State Street Corp | $627,268.00 | 4.25% | 21.79M | +12,206 | +0.06% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $460,215.00 | 3.12% | 15.99M | +1M | +7.66% | 2024-12-31 |
| Bank Of New York Mellon Corp | $442,187.00 | 2.99% | 15.36M | +3M | +22.33% | 2024-12-31 |
| Geode Capital Management, Llc | $358,347.00 | 2.43% | 12.45M | +290,279 | +2.39% | 2024-12-31 |
| Invesco Ltd. | $270,120.00 | 1.83% | 9.38M | +2M | +19.2% | 2024-12-31 |
| Harris Associates L P | $243,656.00 | 1.65% | 8.46M | -1M | -13.43% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Price to Earnings
Price/Earnings to Growth
Price to Sales
Price to Book
Price/Free Cash Flow
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.